Context Therapeutics is trading at $0.20, up 5.36%; biotech strength and a broad-market rally may be supporting the move, but no direct cause is established. - No clear company-specific catalyst was identified for November 4, 2026. - Available news listings show the September 9 CT-202 trial update as the latest company release; XBI was up 2.13%.